Key result
Urban LVAD recipients had greater initial improvements in heart failure-specific quality of life compared with rural recipients (difference 13.0 ± 5.6, p=.02), but subsequent changes were similar.
Why the study?
No studies had compared heart failure-specific or generic HRQOL between rural and urban LVAD recipients.
Does health-related quality of life differ longitudinally between rural and urban recipients of left ventricular assist devices?
Cohort (n=95)
Does health-related quality of life differ longitudinally between rural and urban recipients of left ventricular assist devices?
Mean Difference: 13
p-value: p=.02
While urban LVAD recipients experience greater initial improvements in heart failure-specific quality of life, both rural and urban patients achieve comparable long-term improvements following implantation.
Long-term QoL gains appear similar regardless of residence after LVAD; hypothesis-generating regarding urban-rural disparities in early recovery.
Left ventricular assist devices (LVAD) are a common treatment for advanced heart failure (HF) to improve ventricular function, symptoms, and health-related quality of life (HRQOL). Many LVAD recipients travel long distances from rural areas for LVAD implantation and follow-up care. Individuals with HF in rural settings who have not undergone LVAD implantation have reported poor HRQOL. However, to date, no studies have compared HF-specific or generic HRQOL in rural and urban LVAD recipients. The purpose of this study was to compare generic and HF-specific HRQOL longitudinally from preimplantation to 1-, 3-, and 6- months postimplant in a cohort of rural and urban LVAD recipients (n = 95; rural n = 32 and urban n = 63). We measured generic HRQOL using the European Quality of Life Visual Analog Scale and HF-specific HRQOL with the quality of life domain of the Kansas City Cardiomyopathy Questionnaire (KCCQ). Latent growth curve modeling identified two phases of change in generic and HF-specific HRQOL: the initial response to LVAD between preimplantation and 1-month postimplant and the subsequent change between 1- and 6-months postimplant. Comparable improvements in generic HRQOL were noted in rural and urban LVAD recipients during both phases of change. Urban LVAD recipients had greater initial improvements in HF-specific HRQOL (KCCQ) compared with rural recipients (13.0 ± 5.6, p = .02), but subsequent improvements were similar among rural and urban recipients. Ongoing assessment of generic and HF-specific HRQOL is necessary during LVAD therapy.
No takes yet. Share an insight, caveat, or question.
Alonso et al. (2020) conducted a cohort in advanced heart failure (n=95). Urban residence vs. Rural residence was evaluated on HF-specific HRQOL (KCCQ) initial improvement (13.0 ± 5.6, p=.02). Urban LVAD recipients had greater initial improvements in heart failure-specific quality of life compared with rural recipients (difference 13.0 ± 5.6, p=.02), but subsequent changes were similar.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: